See more : Yoshimura Food Holdings K.K. (2884.T) Income Statement Analysis – Financial Results
Complete financial analysis of ReWalk Robotics Ltd. (RWLK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ReWalk Robotics Ltd., a leading company in the Medical – Devices industry within the Healthcare sector.
- Primetech S.A. (PTH.WA) Income Statement Analysis – Financial Results
- GEOCODE CO.,Ltd. (7357.T) Income Statement Analysis – Financial Results
- Anhui Anli Material Technology Co., Ltd. (300218.SZ) Income Statement Analysis – Financial Results
- TDb Split Corp. (XTD.TO) Income Statement Analysis – Financial Results
- Macondray Capital Acquisition Corp. I (DRAYW) Income Statement Analysis – Financial Results
ReWalk Robotics Ltd. (RWLK)
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Ilit, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13.85M | 5.51M | 5.97M | 4.39M | 4.87M | 6.55M | 7.75M | 5.87M |
| Cost of Revenue | 9.40M | 3.61M | 3.06M | 2.20M | 2.15M | 3.72M | 4.65M | 5.13M |
| Gross Profit | 4.45M | 1.91M | 2.90M | 2.19M | 2.73M | 2.83M | 3.10M | 736.00K |
| Gross Profit Ratio | 32.14% | 34.57% | 48.66% | 49.83% | 55.94% | 43.16% | 40.00% | 12.54% |
| Research & Development | 4.15M | 4.03M | 2.94M | 3.46M | 5.35M | 7.35M | 6.04M | 9.03M |
| General & Administrative | 10.00M | 7.13M | 5.63M | 4.98M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 13.92M | 9.84M | 6.99M | 5.75M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.92M | 16.98M | 12.62M | 10.73M | 11.43M | 14.69M | 19.05M | 22.15M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 28.07M | 21.01M | 15.56M | 14.19M | 16.77M | 22.04M | 25.09M | 31.18M |
| Cost & Expenses | 37.47M | 24.61M | 18.62M | 16.40M | 18.92M | 25.76M | 29.75M | 36.31M |
| Interest Income | 1.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 |
| Interest Expense | 20.00K | 22.00K | 25.00K | 907.00K | 1.53M | 2.42M | 2.48M | 2.01M |
| Depreciation & Amortization | 1.85M | 202.00K | 266.00K | 285.00K | 321.00K | 463.00K | 642.00K | 696.00K |
| EBITDA | -21.77M | -18.90M | -12.39M | -11.73M | -13.72M | -18.79M | -21.48M | -29.79M |
| EBITDA Ratio | -157.10% | -343.35% | -208.30% | -267.29% | -281.70% | -286.49% | -275.38% | -506.82% |
| Operating Income | -23.61M | -19.10M | -12.66M | -12.00M | -14.05M | -19.21M | -21.99M | -30.44M |
| Operating Income Ratio | -170.43% | -346.62% | -212.12% | -273.25% | -288.28% | -293.57% | -283.66% | -518.67% |
| Total Other Income/Expenses | 1.47M | 0.00 | 13.00K | -921.00K | -1.50M | -2.47M | -2.61M | -2.06M |
| Income Before Tax | -22.15M | -19.10M | -12.64M | -12.93M | -15.54M | -21.68M | -24.60M | -32.50M |
| Income Before Tax Ratio | -159.85% | -346.62% | -211.90% | -294.22% | -318.98% | -331.25% | -317.27% | -553.76% |
| Income Tax Expense | -12.00K | 467.00K | 94.00K | 51.00K | 7.00K | -5.00K | 119.00K | 3.00K |
| Net Income | -22.13M | -19.57M | -12.74M | -12.98M | -15.55M | -21.68M | -24.72M | -32.50M |
| Net Income Ratio | -159.76% | -355.09% | -213.48% | -295.38% | -319.13% | -331.17% | -318.81% | -553.81% |
| EPS | -2.59 | -2.20 | -1.86 | -5.74 | -18.90 | -103.04 | -213.98 | -431.63 |
| EPS Diluted | -2.59 | -2.20 | -1.86 | -5.74 | -18.90 | -103.04 | -213.98 | -431.63 |
| Weighted Avg Shares Out | 8.53M | 8.91M | 6.85M | 2.25M | 823.33K | 210.36K | 115.51K | 75.30K |
| Weighted Avg Shares Out (Dil) | 8.53M | 8.91M | 6.85M | 2.25M | 823.33K | 210.36K | 115.51K | 75.30K |
ReWalk Robotics Stock Up 56%: Great Origin Story, Poor Financial Prospects
These Penny Stocks Are Popular On Reddit, Are They On Your Watchlist?
5 Penny Stocks to Watch That Exploded Today, What You Need to Know
RWLK Stock: Why It Significantly Increased Today
Universal Music Group IPO: 8 Things for Potential UMG Stock Investors to Know as Shares Debut
RWLK Stock Short-Squeeze Watch: What to Know as ReWalk Robotics Investors Burn the Shorts
ReWalk Robotics Ltd. (RWLK) CEO Larry Jasinski on Q2 2021 Results - Earnings Call Transcript
ReWalk Robotics (RWLK) Reports Q2 Loss, Tops Revenue Estimates
ReWalk Robotics to Report Second Quarter 2021 Financial Results on August 9, 2021
ReWalk Robotics Appoints Senior Biotech Executive, Jeannine Lynch, as Vice President of Strategy and Market Access
Source: https://incomestatements.info
Category: Stock Reports